Transaction #18910 · Form 4 · 0001193125-25-317191
Hyperliquid Strategies Inc · Other acquisition · Warrants
Hyperliquid Strategies Inc · Transacted December 2, 2025 · Filed December 12, 2025
What does this filing report?
An SEC Form 4 filing for Hyperliquid Strategies Inc records an other acquisition involving Warrants on December 2, 2025. The reported quantity was 16,000. The filing date is December 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Hyperliquid Strategies Inc
- Company CIK
- 0002078856
- Security type
- Derivative
- Acquisition type
- Other acquisition · Code J
- Quantity acquired
- 16,000
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 16,000
- Ownership description
- See Footnote
- SEC acceptance time
- Dec 12, 2025, 11:52 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- TUDER JEFFREY ↗
Director
CIK 0001671976
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 16,000
- Conversion / exercise price
- 6.25
- Exercise date
- December 2, 2025
- Expiration date
- July 14, 2025
Filing footnotes & remarks
- F1
- On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Tremson Capital Management, LLC ("Tremson") received 8,188 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock"), in exchange of certain securities of Sonnet Tremson held prior to the Closing.
- F2
- The securities are held directly by Tremson and indirectly by Jeffrey Tuder, managing member of Tremson. Mr. Tuder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- F3
- In connection with the Closing, Tremson received warrants to purchase an aggregate of 16,000 shares of Common Stock, at an initial exercise price of $6.25 per share, in exchange of certain warrants of Sonnet Tremson held prior to the Closing.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.